Skip to main content
Journal of Clinical Biochemistry and Nutrition logoLink to Journal of Clinical Biochemistry and Nutrition
. 2024 Apr 10;75(1):65–70. doi: 10.3164/jcbn.24-56

Intragastric bacterial infection and endoscopic findings in Helicobacter pylori-negative patients

Takashi Kawai 1,*, Yusuke Kawai 1, Yoshika Akimito 1, Mariko Hamada 1, Eri Iwata 1, Ryota Niikura 1, Naoyoshi Nagata 1, Kyosuke Yanagisawa 1, Masakatsu Fukuzawa 2, Takao Itoi 2, Mitsushige Sugimoto 3
PMCID: PMC11273264  PMID: 39070535

Abstract

In the present study, the authors examined the association between gastric bacterial infection and gastric endoscopic findings in Helicobacter pylori (H. pylori)-negative patients. The subjects were 105 H. pylori-negative patients. The mean age was 72.8 ± 9.1 years. Endoscopy and gastric juice culture were performed. The presence or absence of endoscopic findings was checked according to the Kyoto classification of gastritis. Culture was positive in 69 patients (65.7%), with Streptococcus α-hemolytic being the most common (51 patients), followed by Neisseria sp. (43 patients). According to the univariate analysis, there was a significant difference between the results of culture and background factors in the use of gastric antisecretory drugs and between the results of culture and various endoscopic findings in atrophic gastritis, intestinal metaplasia, regular arrangement of collecting venule, mucosal swelling, sticky mucus, hyperplastic polyps, hematin, and gastric cobblestone-like lesions. Furthermore, multivariate analysis revealed significant differences in background factors such as the use of gastric antisecretory drugs and endoscopic findings only in patients with mucosal swelling. Endoscopic findings of non-H. pylori bacteria-positive gastritis differed from endoscopic findings of H. pylori-infected gastritis in several respects. In conclusion, our results suggest that non-H. pylori bacteria may infect the stomach and cause gastric inflammation, especially in patients who long term use gastric antisecretory drugs.

Keywords: intragastric bacterial infection, proton pump inhibitors, gastric antisecretory drugs, Kyoto classification of gastritis, non-H. pylori infection

Introduction

The stomach is an acidic environment where bacteria cannot live, but Dr. Warren and Dr. Marshall reported in the Lancet in 1983 that Helicobacter pylori (H. pylori) can infect the stomach.(1) H. pylori mainly infects the gastric mucosa during childhood. H. pylori infection in the stomach during childhood causes gastritis in all patients, followed by persistent infection and active gastritis, which progresses from gastritis, such as nodular gastritis, to atrophic gastritis and intestinal metaplasia. According to Correa’s hypothesis, pathological and epidemiological studies have shown that H. pylori infection of the normal gastric mucosa leads to a multistep process of chronic gastritis, atrophy, intestinal metaplasia, and dysplasia. A hypothesis regarding a human model of carcinogenesis has been reported.(2)

In recent years, there have been remarkable advances in research methods in the field of bacteriology. As new molecular biological methods such as 16S rRNA gene sequencing using next-generation sequencing have enabled detailed identification of bacteria in the gastric mucosa, researchers have made new reports regarding the role of non-H. pylori bacteria in the development of gastric cancer. In the past, only H. pylori infecting the gastric mucosa was thought to be involved in the transition from normal gastric mucosa to gastric carcinogenesis. Stewart et al.(3) reported that the amount of H. pylori in the gastric mucosa increases after initial infection, especially during the stage of active gastritis. Furthermore, it was reported that the bacterial amount of H. pylori is much lower in gastric cancer patients than in patients with gastritis.(4) This phenomenon can be explained by the fact that after H. pylori infection, inflammation persists, and acid-secreting parietal cells disappear, making the gastric environment favorable for the formation of other bacterial colonies and accelerating the progression of chronic gastritis to atrophic gastritis and intestinal metaplasia.(5) In addition, it was reported that commensal oral or intestinal microorganisms become enriched as chronic gastritis progresses to atrophic gastritis and intestinal metaplasia.(6,7) In the later stages of gastric precancerous lesions, the gastric environment is no longer suitable for H. pylori, and the amount of H. pylori decreases. This phenomenon has been confirmed in human studies.(4,5)

Hirschl et al.(810) reported that H. pylori is present in the gastric mucosa of more than 90% of patients with active acute gastritis, but in the majority of patients with advanced atrophic gastritis, intestinal metaplasia or gastric cancer, H. pylori is absent in the gastric mucosa even when the anti-H. pylori antibody test is positive. Karnes et al.(11) reported that H. pylori infection disappears in advanced stages of gastric carcinogenesis. At present, the detailed correlation between the diversity of the gastric microbiota and the progression from normal gastric mucosa to gastric cancer has not yet been clarified. Furthermore, there is currently no consensus on the relationship between the diversity of the microbiota and the stage of gastric cancer development. However, it is plausible that an increase or decrease in the diversity of the microbiota in the stomach is associated with the development of gastric cancer.

H. pylori eradication is widely and aggressively practiced worldwide, and in Japan, there were more than 1.6 million cases per year since endoscopic gastritis was covered by insurance in February 2013.(12) H. pylori eradication improves gastric acid secretory capacity, and the stomach is thought to be free of bacteria, including H. pylori.(13) However, recent analyses of microbial sequences revealed distinct microbial clusters reflecting an increase in bacterial diversity (p<0.00001) after 1 year of eradication, indicating that gastric bacteria, mainly oral bacteria, are involved in the progression of gastric carcinogenesis after H. pylori eradication.(14)

The H. pylori infection rate was more than 70% in the 1970s but rapidly declined to the 20% range in the 2000s.(15) In 2018, the annual infection rate among 35-year-olds was reported to be less than 1 in 10, with 10.1% for males and 9.2% for females.(16) The number of H. pylori-negative patients is clearly increasing, as H. pylori eradication is also progressing. Nishizawa et al.(17) reported a increase in H. pylori uninfected gastric cancer in recent years. This is also accompanied by an increase in reflux esophagitis, an acid-related disease, as well as the prescription of low-dose aspirin for secondary prevention of cerebral and myocardial infarction and NSAIDs for knee arthritis and lumbago due to the aging of the population. Proton pump inhibitors (PPIs) or histamine 2-receptor antagonists (H2As) are recommended in guidelines for the initial and maintenance treatment of reflux esophagitis and for the prevention of aspirin and NSAID ulcers, and their long-term use is increasing.(18,19) Since their marketing, there have been concerns about the effects of PPIs on the development of gastric cancer due to their strong inhibition of gastric acid secretion.(20) The acidic environment of the stomach is the first line of defense against orally ingested bacteria. When the intragastric pH is greater than 4, bacterial colony formation becomes possible in the stomach, and the positivity rate of non-H. pylori bacteria in the gastric juice increase, and they settle in the gastric mucosa in long-term use of PPIs.(21)

Nagata et al. constructed a large database integrating lifestyle and clinical information with the gut microbiome by shotgun metagenomic sequencing of fecal samples from approximately 4,000 Japanese subjects and comprehensively investigated factors affecting the gut microbiome and reported that long-term PPI administration had the greatest impact on the gut microbiome.(22) It is possible that gastrointestinal bacterial infections other than H. pylori, mainly oral bacteria, occur in the stomach. In this study, we performed gastric juice culture tests during endoscopy in H. pylori-negative patients. We also investigated the status of non-H. pylori bacteria and endoscopic gastritis findings. We also examined the relationship between gastric juice culture and lifestyle habits, as well as the use of gastric antisecretory drugs.

Methods

Participants

This retrospective study was conducted at Tokyo Medical University Hospital to investigate the gastric microflora and gastrointestinal endoscopic findings. The study protocol adhered to the ethical principles of the Declaration of Helsinki and was approved by the institutional review board of Tokyo Medical University (T2023-0134). Because this study was retrospective in design and written informed consent was not obtained from each enrolled patient, a document describing an opt-out policy through which potential patients and/or relatives could refuse inclusion was uploaded to the Tokyo Medical University Hospital website.

The subjects were 105 patients who underwent upper endoscopy for upper gastrointestinal screening and surveillance between May 1, 2023, and September 20, 2022. The mean age was 72.8 ± 9.1 years, and the male-to-female ratio was 1.23:1. The physicians performing the endoscopies were specialists of the Japan Gastroenterological Endoscopy Society and excluded patients younger than 20 years, older than 90 years, who were taking antimicrobial agents, and who had undergone gastric resection. The scope used in this study was the GIF-1200 N (Olympus Medical Systems Corporation, Tokyo, Japan). The optical source was an EVIS X1 system (Olympus Medical Systems).

Endoscopy and gastric juice culture

Gastric juice collection: After an endoscope was inserted into the stomach, approximately 10 ml of gastric juice containing gastric mucus was collected from the forceps channel. Blood agar (Trypticase Soy Agar with 5% Sheep Blood) and chocolate II agar (Chocolate II Agar, BD, Fukushima, Japan) were used as culture media. After the media were added to the specimens, both media were incubated with carbon dioxide at 35°C overnight for 24 h. The medium was observed to identify the bacteria that developed. The chocolate medium was then incubated with carbon dioxide at 35°C for another 24 h, the blood agar medium was incubated at aerobic room temperature, and the medium was observed and analyzed again.

The presence or absence of H. pylori infection was checked by the H. pylori antibody test and 13C-urea breath test.

Endoscopic findings

Endoscopic findings were evaluated using the Kyoto classification of gastritis.(23) To assess the presence of endoscopic gastritis, atrophy, intestinal metaplasia, enlarged folds, tortuous folds, nodularity, diffuse redness, regular arrangement of collecting venules (RACs), fundic gland polyps, map-like redness, mucosal swelling, sticky mucus, spotty redness, foveolar-hyperplastic polyps, xanthomas, hematin, red streaks, raised erosions, multiple white and flat elevated lesions, patchy redness, depressed erosions, body erosions, sticky adherent dense mucus, and gastric cobblestone-like lesions were evaluated. Atrophy, intestinal metaplasia, enlarged folds, tortuous folds, nodularity, and diffuse redness were scored using the Kyoto classification of gastritis.

Statistical analysis

Age and Kyoto classification of gastritis scores are expressed as the mean ± SD. Comparisons between positive and negative results for each factor and among different dosed drugs (no drug, on demand, H2As, PPIs, and P-CAB) were analyzed by t tests and one-way ANOVA, respectively. Categorized variables such as sex, smoking status, alcohol consumption status, H. pylori status, culture status, and any endoscopic findings are expressed as n numbers, and contingency table analysis (chi-square test) was used to examine differences between positive and negative factors and among different doses of drugs. Multivariate logistic regression analyses were used to test the associations of candidate variables with positive culture results using gastric juice. P<0.05 was considered to indicate statistical significance, and all p values were two-sided. Calculations were conducted using SPSS ver. 28 (IBM, Inc., Armonk, NY).

Results

Patient background

The ratio of patients who did and did not smoke was 4:101, and the ratio of patients who did and did not drink was 33:72. For H. pylori infection, the ratio of previously infected to uninfected individuals was 82:23. The ratio of patients with and without gastric antisecretory drug use was 55:50, which is almost equal. The H2A/PPI/P-CAB ratio was 3:33:19. PPIs and P-CABs were prescribed for at least 1 year. Four of the PPIs and 4 of the P-CABs were taken on so-called on-demand.

Gastric fluid culture results

Sixty-nine (65.7%) of the cultures were positive for Streptococcus-α-hemolytic bacteria, the largest number (51), followed by Neisseria sp. (41) and Streptococcus sp. (33). Group c included Streptococcus (3 patients), Staphylococuus aureus (10 patients), Staphylococuus epdermidis (1 patient), Rothia sp. (1 patient), Yeast sp. (4 patients), Enterobacter aerogenes (CRE) (1 patient), Enterococcus faecalis (2 patients), Escherichia coli (3 patients), Haemophilus parainfluenzae (5 patients), Haemophilus parahamolyticus (1 patient), Haemophilus hamolyticus (2 patients), Bacillus subtilis (7 patients), Bacillus cereus (1 patient), Bacillus sp. (7 patients), Corynebacterium sp. (3 patients), Candida albicans (5 patients), Candida glabrata (1 patient), and Acinetobacter baumanii (1 patient).

No significant differences were found in the relationships between culture positivity/negativity and smoking status, alcohol consumption, or past H. pylori infection, and a significant association was found between the use of gastric antisecretory drugs and no gastric antisecretory drugs, on demand, or continuous daily oral administration. However, no differences were found between H2A, PPI and P-CAB (Table 1).

Table 1.

Characteristics of patients

Factors
Patients number 105
Sex male/female 58/47
Age (year ± SD) 73.9 ± 9.1
Smoking −/+ 101/4
Alcohol −/+ 72/33
H. pylori infection Never infection/Previous infection 23/82
Acid inhibitor −/+ 50/55
Essential use H2RA/PPI/P-CAB 3/28/16

Endoscopic findings

The relationships between the culture results and various endoscopic findings are shown in Table 2. Positive culture results were significantly associated with atrophic gastritis, intestinal metaplasia, mucosal swelling, sticky mucus, hyperplastic polyps, sticky adherent dense mucus, and gastric cobblestone-like lesions. On the other hand, significant associations were found for culture negativity, RAC, and hematin.

Table 2.

Factors associatied wit culture test positivity

Factors Positive Negative p value
Patients number 69 36
Sex male/female 36/33 22/14 0.382
Age (year ± SD) 73.3 ± 9.8 71.8 ± 7.6 0.409
Smoking −/+ 67/2 34/2 0.500
Alcohol −/+ 51/18 21/15 0.103
H. pylori infection Never infection/Previous infection 15/54 8/28 0.955
Acid inhibitor −/+ 20/49 30/6 <0.001
−/on demand/essential use 20/3/46 30/5/1 <0.001
Essential use H2A/PPI/P-CAB 3/27/16 0/1/0 0.707
Endoscopy
Kyoto classification of gastritis Atrophy 1.45 ± 0.76 1.08 ± 0.69 0.017
Intestinal metaplasia 1.35 ± 0.84 0.97 ± 0.77 0.027
Enlarged fold 0.01 ± 0.12 0.00 ± 0.00 0.473
Nodularity 0.00 ± 0.00 0.00 ± 0.00
Diffuse redness 0.00 ± 0.17 0.00 ± 0.00 0.307
Total score 2.83 ± 1.55 2.03 ± 1.32 0.010
RAC −/+ 42/27 10/26 0.001
Fundic gland polyp −/+ 50/19 26/10 0.979
Reddished fundic gland polyp −/+ 17/2 10/0 0.567
Map-like redness −/+ 63/6 29/7 0.112
Edematous mucosa −/+ 21/48 32/4 <0.001
Spotty redness −/+ 68/1 36/0 0.468
Sticky mucous −/+ 44/25 35/1 <0.001
Visible vascular pattern −/+ 66/3 36/0 0.204
Hyperplastic polyp −/+ 42/27 29/7 0.041
Xanthoma −/+ 61/8 33/3 0.605
Hematin −/+ 62/7 25/11 0.008
Red streak −/+ 67/2 35/1 0.972
Raised erision −/+ 64/5 32/4 0.697
Multiple white and flat elevated lesions −/+ 55/14 27/9 0.754
Pathy redness −/+ 67/2 36/0 0.302
Depressed erosion −/+ 63/6 31/5 0.523
Erosion in body −/+ 69/0 33/3 0.051
Sticky adherent dense mucus −/+ 57/12 36/0 0.008
Cobblestone-like appearance −/+ 56/13 35/1 0.022

According to the univariate analysis, there was a significant difference between the results of gastric juice culture and background factors in the use of gastric antisecretory drugs and between the results of gastric juice culture and various endoscopic findings in atrophic gastritis, intestinal metaplasia, RAC, mucosal swelling, sticky mucus, hyperplastic polyps, hematin, and gastric cobblestone-like lesions (Table 3 and 4). Furthermore, multivariate analysis revealed significant differences in background factors, such as the use of gastric acid secretion inhibitors and endoscopic findings, but only in mucosal swelling (Table 3 and 4).

Table 3.

Univariate and Multivariate analysis for positive of culture test with reference to background

Factors Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Sex Female 1.44 0.635–3.270 0.383
Age (year ± SD) 1.019 0.975–1.065 0.406
Smoking + 0.507 0.068–3.761 0.507
Alcohol + 0.494 0.211–1.160 0.105
H. pylori infection Never infection/Previous infection 0.972 0.368–2.570 0.955
Acid inhibitor + (including on demand + essential) 12.25 4.421–33.944 <0.001 4.600 1.209–17.496 0.035

Table 4.

Univariate and Multivariate analysis for positive of culture test with reference to endoscopic findings

Factors Univariate Multivariate
OR 95% CI p value OR 95% CI p value
Endoscopy
Kyoto classification of gastritis Atrophy 1.911 1.108–3.298 0.020 2.904 0.849–9.929 0.089
Intestinal metaplasia 1.729 1.056–2.831 0.030 1.021 0.349–2.985 0.97
Enlarged fold
Nodularity
Diffuse redness
Total score 1.420 1.080–1.867 0.012
RAC −/+ 0.247 0.103–0.593 0.002 1.545 0.396–6.027 0.531
Fundic gland polyp −/+ 0.988 0.401–2.431 0.979
Map-like redness −/+ 0.395 0.122–1.279 0.121
Edematous mucosa −/+ 17.524 5.491–55.930 <0.001 7.125 1,638–30.986 0.009
Spotty redness −/+
Sticky mucous −/+ 19.855 2.567–154.087 0.004 3.108 0.267–36.196 0.365
Visible vascular pattern −/+
Hyperplastic polyp −/+ 2.633 1.023–6.932 0.045 1.303 0.302–5.614 0.722
Xanthoma −/+ 1.433 0.358–5.808 0.606
Hematin −/+ 0.257 0.089–0.737 0.012 0.707 0.189–2.655 0.608
Red streak −/+ 1.045 0.092–11.927 0.972
Raised erision −/+ 0.500 0.117–2.130 0.349
Multiple white and flat elevated lesions −/+ 0.764 0.294–1.986 0.58
Pathy redness −/+
Depressed erosion −/+ 0.590 0.167–2.086 0.413
Erosion in body −/+ 0.826 0.152–4.498 0.825
Sticky adherent dense mucus −/+
Cobblestone-like appearance −/+ 8.125 1.018–64.863 0.048 2.570 0.208–31.767 0.462

Discussion

Over the past decade, we have come to understand the critical role of microorganisms in the maintenance of health and disease. Biome science, or the study of microbial communities, has grown exponentially in this short period of time. The intestinal microenvironment is composed of microorganisms, the intestinal epithelium, and the local immune system. Microorganisms inhabiting the human gastrointestinal tract include not only bacteria but also viruses and fungi. Diet, breastfeeding, environmental exposure, and genetic factors determine how these microbes develop, and external factors such as antibiotics, mode of birth, and diet affect the microbiome, which appears to be most affected in childhood.(24,25) What is important is the relative abundance and diversity of the microbiome, not just the specific microbes that inhabit a particular environment.(26) The oral microbiome has been implicated in both local disease states, such as dental caries, periodontitis, and oral cancer, and more distant diseases, such as inflammatory bowel disease, pancreatic cancer, and obesity.(27) Although microbiome research has focused on the colon, it is important to understand that other parts of the gut inhabited by microbiota that influence metabolism are also present, namely, the oral cavity and small intestine.(28,29) Compared to those in the large intestine, the absolute (several orders of magnitude) and relative abundances of microorganisms are much lower in the oral cavity and small intestine.

In this gastric juice culture, most of the species detected were Streptococcus spp. and Neisseria spp. This result is similar to that of Furuta et al.,(30) and it seems safe to assume that gastric juice culture and gastric mucosa culture yield similar results. Furthermore, Zilberstein et al.(31) reported that the oral flora was dominated by Streptococcus and Neisseria species, and many of the bacteria detected in the stomach in this study were thought to be of oral origin. Furthermore, PPIs, P-CABs, and other gastric antisecretory drugs were significantly associated with positive gastric juice culture findings in both univariate and multivariate analyses. These results suggest that in long-term patients taking strong gastric antisecretory drugs, an intragastric pH of 4 or higher facilitates the formation of bacterial colonies in the stomach, and non-H. pylori bacteria, such as oral bacteria, may proliferate and infect the gastric mucosa.

Gastritis has been used as a generic term for symptomatic gastritis, endoscopic gastritis, and histological gastritis. Symptomatic gastritis without organic disease has been proposed as an independent disease concept as functional dyspepsia, and gastritis = histological gastritis. In 2007, the Japan Gastroenterological Endoscopy Society established a study group to establish an endoscopic diagnosis of chronic gastritis with the aim of matching histological gastritis and endoscopic findings. Five articles were published in Dig Endosc, after which the endoscopic diagnosis of H. pylori-infected gastritis was established.(3236) The Kyoto Classification of Gastritis was published to promote the endoscopic diagnosis of H. pylori-infected gastritis via endoscopic screening for gastric cancer.

In this study, atrophic gastritis, intestinal metaplasia, mucosal swelling, sticky mucus, hyperplastic polyps, and gastric cobblestone-like lesions were associated with positive gastric juice culture, while RAC and hematin were associated with negative gastric juice culture. Yoshi et al.(37) evaluated endoscopic findings according to the Kyoto classification of H. pylori infection status in 498 patients. They found that RAC [odds ratio (OR): 32.2], fundic gland polyps (OR: 7.7), and red streaks (OR: 4.7) in noninfected patients; map-like redness (OR: 12.9) in those with past infection; diffuse redness (OR: 26.8), mucosal swelling (OR: 13.3), and white mucus (OR: 10.2); and enlarged folds and tortuous folds (OR: 8.6) were significantly more likely to be associated with a diagnosis. Endoscopic findings of non-H. pylori bacteria-positive gastritis differed from endoscopic findings of H. pylori-infected gastritis in several respects.

Mucosal swelling and sticky mucus, as well as diffuse redness, are considered basic findings that indicate active gastritis (histologically, especially reflecting neutrophilic infiltration) and are reported as typical endoscopic findings of H. pylori-infected gastritis.(23) Although diffuse redness was not observed in this study, mucosal swelling and sticky mucus were observed in the oral bacteria-positive gastric mucosa, suggesting that inflammation may have been induced.

Hyperplastic polyps are thought to be inflammatory polyps formed by inflammatory cellular infiltration. Histologically, they are characterized by dilation of the glandular ducts and large and small cystic dilatations due to epithelial hyperplasia of the glandular fossa. Hyperplastic polyps were previously thought to be caused by inflammation associated with H. pylori-associated gastritis, but now, they should also be considered to be caused by inflammation associated with non-H. pylori bacterial gastritis.(38) It is necessary to examine whether PPI withdrawal and other measures can eliminate oral bacteria-associated hyperplastic polyps.

Hatta et al.(39) investigated differences between acid secretion and endoscopic findings in 223 subjects and reported that the acid secretion capacity was significantly greater in patients with endoscopic findings of hematin. RAC is an endoscopic image of regularly arranged collecting venules in the body of the stomach. RAC is considered to be an endoscopic finding that is not infected with oral bacteria, as reported as a typical endoscopic image of a normal stomach uninfected with H. pylori.(40)

In this study, atrophic gastritis and intestinal metaplasia may be related to the environment of low acid secretion capacity, and the intragastric environment is favorable for colony formation of indigenous oral or intestinal microorganisms due to long-term administration of PPIs. The pathogenesis of chronic gastritis may be related to the enrichment of oral or intestinal commensal microorganisms as the disease progresses from atrophic gastritis to intestinal metaplasia.(6,7)

Approximately 10.5% of gastric cobblestone-like lesions were reported in patients who had been taking PPIs for more than 6 months.(41) The frequency of detection of gastric cobblestone-like lesions was significantly greater in PPI-treated patients, and similar gastric cobblestone-like lesions were reported in P-CAB-treated patients.(42,43) The effect of PPI administration as well as non-H. pylori bacterial infection is likely to be significant.

Our results suggest that non-H. pylori bacteria may infect the stomach and cause gastric inflammation, especially in patients who use long-term gastric antisecretory drugs.

Limitations

This was a single-center retrospective study. This study is preliminarily based on a conventional gastric juice culture test, not on a genetic analysis, and does not reflect all gastric microbiota. This study used endoscopic diagnosis of gastritis based on the Kyoto classification of gastritis, and histological examination may be necessary in the future.

Author Contributions

Study concept and design, TK; methodology, TK and MS; software, RN, NN, MF, TK, and MS; investigation, TK, KY, YA, MH, and EI; formal analysis, TK and MS; drafting of the manuscript, TK and MS; critical revision of the manuscript, MS and TK; supervision, TI and TK; project administration, TK.

Acknowledgments

No specific funding was received for the present study.

Conflict of Interest

No potential conflicts of interest were disclosed.

References

  • 1.Warren JR, Marshall BJ. Unidentified curved bacilli on the gastric epithelium in chronic gastritis. Lancet 1983; 1: 1273–1275. [PubMed] [Google Scholar]
  • 2.Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 15: 6735–6740. [PubMed] [Google Scholar]
  • 3.Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes 2020; 11: 1220–1230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Kadeerhan G, Gerhard M, Gao JJ, et al. Microbiota alteration at different stages in gastric lesion progression: a population-based study in Linqu, China. Am J Cancer Res 2021; 11: 561–575. [PMC free article] [PubMed] [Google Scholar]
  • 5.Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018; 67: 226–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403–414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018; 67: 1024–1032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Hirschl A, Pötzi R, Stanek G, et al. Occurrence of campylobacter pyloridis in patients from Vienna with gastritis and peptic ulcers. Infection 1986; 14: 275–278. [DOI] [PubMed] [Google Scholar]
  • 9.Galiatsatos P, Wyse J, Szilagyi A. Accuracy of biopsies for Helicobacter pylori in the presence of intestinal metaplasia of the stomach. Turk J Gastroenterol 2014; 25: 19–23. [DOI] [PubMed] [Google Scholar]
  • 10.Kwak HW, Choi IJ, Cho SJ, et al. Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol 2014; 29: 1671–1677. [DOI] [PubMed] [Google Scholar]
  • 11.Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 1991; 101: 167–174. [DOI] [PubMed] [Google Scholar]
  • 12.Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter 2017; 22: e12415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther 2004; 19: 1181–1188. [DOI] [PubMed] [Google Scholar]
  • 14.Sung JJY, Coker OO, Chu E, et al. Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication. Gut 2020; 69: 1572–1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Hirayama Y, Kawai T, Otaki J, Kawakami K, Harada Y. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol 2014; 29 Suppl 4: 16–19. [DOI] [PubMed] [Google Scholar]
  • 16.Abiko S, Hirayama Y, Otaki J, et al. Changes in prevalence of Helicobacter pylori in Japan from 2008 to 2018: a repeated cross-sectional study. BMJ Open 2022; 12: e058774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Nishizawa T, Yoshida S, Toyoshima A, et al. Increasing trend of Helicobacter pylori-uninfected gastric cancer without gastric atrophy. J Clin Biochem Nutr 2022; 71: 245–248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 2021; 56: 303–322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol 2022; 57: 267–285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wormsley KG. Is hypergastrinaemia dangerous for man? Scand J Gastroenterol Suppl 1991; 180: 174–178. [DOI] [PubMed] [Google Scholar]
  • 21.Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001; 15: 379–388. [DOI] [PubMed] [Google Scholar]
  • 22.Nagata N, Nishijima S, Miyoshi-Akiyama T, et al. Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 2022; 163: 1038–1052. [DOI] [PubMed] [Google Scholar]
  • 23.Haruma K, Kato M, Inoue K, Murakami K, Kamada T. Kyoto Classification of Gastritis. Tokyo: Nihon Medical Center, 2017. [Google Scholar]
  • 24.Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature 2018; 555: 210–215. [DOI] [PubMed] [Google Scholar]
  • 25.Bokulich NA, Chung J, Battaglia T, et al. Antibiotics, birth mode, and diet shape microbiome maturation during early life. Sci Transl Med 2016; 8: 343ra82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207–214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gao L, Xu T, Huang G, Jiang S, Gu Y, Chen F. Oral microbiomes: more and more importance in oral cavity and whole body. Protein Cell 2018; 9: 488–500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sugitani Y, Inoue R, Inatomi O, et al. Mucosa-associated gut microbiome in Japanese patients with functional constipation. J Clin Biochem Nutr 2021; 68: 187–192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Naito Y. Gut frailty: its concept and pathogenesis. Digestion 2024; 105: 49–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther 2018; 48: 370–377. [DOI] [PubMed] [Google Scholar]
  • 31.Zilberstein B, Quintanilha AG, Santos MA, et al. Digestive tract microbiota in healthy volunteers. Clinics (Sao Paulo) 2007; 62: 47–54. [DOI] [PubMed] [Google Scholar]
  • 32.Kato T, Yagi N, Kamada T, et al. Diagnosis of Helicobacter pylori infection in gastric mucosa by endoscopic features: a multicenter prospective study. Dig Endosc 2013; 25: 508–518. [DOI] [PubMed] [Google Scholar]
  • 33.Nomura S, Terao S, Adachi K, et al. Endoscopic diagnosis of gastric mucosal activity and inflammation. Dig Endosc 2013; 25: 136–146. [DOI] [PubMed] [Google Scholar]
  • 34.Nomura S, Ida K, Terao S, et al. Endoscopic diagnosis of gastric mucosal atrophy: multicenter prospective study. Dig Endosc 2014; 26: 709–719. [DOI] [PubMed] [Google Scholar]
  • 35.Fukuta N, Ida K, Kato T, et al. Endoscopic diagnosis of gastric intestinal metaplasia: a prospective multicenter study. Dig Endosc 2013; 25: 526–534. [DOI] [PubMed] [Google Scholar]
  • 36.Kato M, Terao S, Adachi K, et al. Changes in endoscopic findings of gastritis after cure of H. pylori infection: multicenter prospective trial. Dig Endosc 2013; 25: 264–273. [DOI] [PubMed] [Google Scholar]
  • 37.Yoshii S, Mabe K, Watano K, et al. Validity of endoscopic features for the diagnosis of Helicobacter pylori infection status based on the Kyoto classification of gastritis. Dig Endosc 2020; 32: 74–83. [DOI] [PubMed] [Google Scholar]
  • 38.Ohkusa T, Takashimizu I, Fujiki K, et al. Disappearance of hyperplastic polyps in the stomach after eradication of Helicobacter pylori. A randomized, clinical trial. Ann Intern Med 1998; 129: 712–715. [DOI] [PubMed] [Google Scholar]
  • 39.Hatta W, Iijima K, Koike T, et al. Endoscopic findings for predicting gastric acid secretion status. Dig Endosc 2015; 27: 582–589. [DOI] [PubMed] [Google Scholar]
  • 40.Yagi K, Honda H, Yang JM, Nakagawa S. Magnifying endoscopy in gastritis of the corpus. Endoscopy 2005; 37: 660–666. [DOI] [PubMed] [Google Scholar]
  • 41.Takahari K, Haruma K, Ohtani H, et al. Proton pump inhibitor induction of gastric cobblestone-like lesions in the stomach. Intern Med 2017; 56: 2699–2703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Kiso M, Ito M, Boda T, et al. Endoscopic findings of the gastric mucosa during long-term use of proton pump inhibitor—a multicenter study. Scand J Gastroenterol 2017; 52: 828–832. [DOI] [PubMed] [Google Scholar]
  • 43.Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol 2017; 11: 1899–1901. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Biochemistry and Nutrition are provided here courtesy of The Society for Free Radical Research Japan

RESOURCES